LivaNova PLC (NASDAQ:LIVN) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 279,403 shares of the company’s stock after selling 9,862 shares during the quarter. Great Lakes Advisors LLC’s holdings in LivaNova were worth $12,939,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Central Pacific Bank Trust Division lifted its holdings in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of LivaNova in the 3rd quarter worth approximately $217,000. Sanctuary Advisors LLC acquired a new position in shares of LivaNova in the 3rd quarter worth approximately $219,000. Edgestream Partners L.P. acquired a new position in shares of LivaNova in the 3rd quarter worth approximately $244,000. Finally, Inceptionr LLC acquired a new stake in LivaNova during the 4th quarter worth approximately $217,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LIVN. Barclays reduced their target price on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. The Goldman Sachs Group dropped their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Finally, Needham & Company LLC dropped their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Stock Performance

LIVN opened at $39.07 on Thursday. The stock has a market cap of $2.12 billion, a P/E ratio of 93.02 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock’s 50 day simple moving average is $46.32 and its 200 day simple moving average is $49.18. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.47.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.